Holen Sie sich die Stockscreener-App
1.44
5.11%
0.07
Handel nachbörslich:
1.42
-0.02
-1.39%
Schlusskurs vom Vortag:
$1.37
Offen:
$1.41
24-Stunden-Volumen:
204.62K
Relative Volume:
0.43
Marktkapitalisierung:
$117.51M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-21.65M
KGV:
-4.336
EPS:
-0.3321
Netto-Cashflow:
$-15.84M
1W Leistung:
+9.92%
1M Leistung:
-5.88%
6M Leistung:
-25.00%
1J Leistung:
+63.62%
1-Tages-Spanne:
$1.375
$1.4568
1-Wochen-Bereich:
$1.23
$1.46
52-Wochen-Spanne:
$0.8778
$3.12
Cardiol Therapeutics Inc Stock (CRDL) Company Profile
Vergleichen Sie CRDL mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CRDL
Cardiol Therapeutics Inc
|
1.44 | 117.51M | 0 | -21.65M | -15.84M | -0.3321 |
|
ZTS
Zoetis Inc
|
163.31 | 73.68B | 9.15B | 2.43B | 2.31B | 5.32 |
|
HLN
Haleon Plc Adr
|
9.46 | 42.77B | 14.26B | 1.55B | 0 | 0.3383 |
|
TAK
Takeda Pharmaceutical Co Adr
|
13.26 | 42.04B | 30.27B | 1.93B | 3.45B | 0.6044 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
21.24 | 24.07B | 16.77B | -959.00M | 1.37B | -0.85 |
|
VTRS
Viatris Inc
|
12.28 | 14.66B | 15.05B | -883.30M | 1.89B | -0.74 |
Cardiol Therapeutics Inc Stock (CRDL) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-06-26 | Eingeleitet | ROTH MKM | Buy |
| 2024-04-22 | Eingeleitet | H.C. Wainwright | Buy |
Cardiol Therapeutics Inc Aktie (CRDL) Neueste Nachrichten
Cardiol Therapeutics Inc. (NASDAQ:CRDL) Short Interest Up 12.4% in December - MarketBeat
Appendix 3Y x4 - Investing News Network
Cardiol Therapeutics Sees Insider Buying From Leadership Team And Board Members - The Deep Dive
Guillermo Torre Purchases 17,240 Shares of Cardiol Therapeutics Inc. (TSE:CRDL) Stock - MarketBeat
Insider Buying: Cardiol Therapeutics Inc. (TSE:CRDL) Senior Officer Buys 18,900 Shares of Stock - MarketBeat
2025 biotech outlook: Small-cap innovators tackling chronic and rare diseases - Proactive financial news
HC Wainwright Has Positive Forecast for CRDL FY2024 Earnings - Defense World
FY2024 Earnings Forecast for CRDL Issued By HC Wainwright - MarketBeat
RAD 202 receives approval to start Phase 1 therapeutic trial - Investing News Network
PRISM MarketView Features Q&A with President and CEO David Elsley: Cardiol Therapeutics Enters Phase 3 Clinical Trial for CardiolRx™ Addressing Patients with Recurrent Pericarditis - The Manila Times
PRISM MarketView Features Q&A with President and CEO David Elsley: Cardiol Therapeutics Enters Phase 3 Clinical Trial for CardiolRx Addressing Patients with Recurrent Pericarditis - Investing News Network
PRISM MarketView Features Q&A with President and CEO David - GlobeNewswire
HC Wainwright Reiterates Buy Rating for Cardiol Therapeutics (NASDAQ:CRDL) - MarketBeat
Cardiex Completes Placement Ahead of CONNEQT US Launch - Investing News Network
BPH Global receives funding commitment of A$100,000 - Investing News Network
Cardiol Therapeutics Inc. (TSE:CRDL) Senior Officer Bernard Lim Acquires 10,000 Shares of Stock - MarketBeat
David Elsley Buys 40,000 Shares of Cardiol Therapeutics Inc. (TSE:CRDL) Stock - MarketBeat
Cardiol Therapeutics (TSE:CRDL) Trading Down 2.1%What's Next? - MarketBeat
Cardiol Therapeutics (TSE:CRDL) Trading Down 2.1% – Here’s What Happened - Defense World
Townsquare Capital LLC Buys New Shares in Cardiol Therapeutics Inc. (NASDAQ:CRDL) - Defense World
Cardiol Therapeutics (STU:CT9) Momentum Rank : 6 (As of Dec. 05, 2024) - GuruFocus.com
Cardiol Therapeutics (OTCMKTS:CRTPF) Shares Down 3.1% – Should You Sell? - Defense World
Cardiol Therapeutics (TSX:CRDL) Price-to-Operating-Cash-Flo - GuruFocus.com
CRDL (Cardiol Therapeutics) 50-Day SMA : $1.88 (As of Dec. 01, 2024) - GuruFocus.com
Cardiol Therapeutics (TSX:CRDL) Enterprise Value : C$168.30 Mil (As of Dec. 01, 2024) - GuruFocus.com
Cardiol Therapeutics (FRA:CT9) Price-to-Free-Cash-Flow : N/A (As of Dec. 01, 2024) - GuruFocus.com
3 Penny Stocks Ready to Break Out in 2025 - MarketBeat
3 Penny Stocks Ready To Break Out In 2025 - Barchart
Cardiol Therapeutics (CRDL-Q) QuotePress Release - The Globe and Mail
Cardiol Therapeutics (FRA:CT9) Cyclically Adjusted Revenue per Share : €0.00 (As of Sep. 2024) - GuruFocus.com
Game-Changing Solution for Heart Inflammation? | David Elsley – Cardiol Therapeutics - The Deep Dive
HC Wainwright Issues Optimistic Estimate for CRDL Earnings - Defense World
Comparing Cardiol Therapeutics (NASDAQ:CRDL) & Gilead Sciences (NASDAQ:GILD) - Defense World
What is HC Wainwright's Forecast for CRDL FY2024 Earnings? - MarketBeat
Equities Analysts Set Expectations for CRDL FY2024 Earnings - Defense World
Cardiol Therapeutics (NASDAQ:CRDL) Earns Buy Rating from HC Wainwright - Defense World
Cardiol Therapeutics (TSE:CRDL) Shares Up 1.8%What's Next? - MarketBeat
Leede Financial Issues Positive Forecast for CRDL Earnings - Defense World
Cardiol Therapeutics (Nasdaq: CRDL) Advances Orphan Drug - openPR
What is Leede Financial’s Estimate for CRDL FY2027 Earnings? - Defense World
What is Leede Financial's Forecast for CRDL FY2024 Earnings? - MarketBeat
Roth Capital Has Negative Outlook for CRDL FY2024 Earnings - MarketBeat
Biotech Initiates Phase III Trial for Heart Disease Drug - Streetwise Reports
Pericarditis Drugs Market Is Expected To Reach $816.6 Million - openPR
Cardiol Therapeutics (NASDAQ:CRDL) Given Buy Rating at HC Wainwright - MarketBeat
What is Leede Financial's Forecast for CRDL FY2027 Earnings? - MarketBeat
CBD-Based Drug Reduces Pericarditis Pain And Inflammation, Shows New Clinical Study - Benzinga
Analyst Says Biotech's Data Supports Advancement Into Phase III - Streetwise Reports
Five Top Heart Health Stocks to Buy Heading into 2025 - Baystreet.ca
Spotlight on Undervalued Nasdaq Stocks: HCWB, CRDL, NIVF, SINT, APLMA Must-Watch This Week! - openPR
Cardiol Therapeutics Inc. - Baystreet.ca
Finanzdaten der Cardiol Therapeutics Inc-Aktie (CRDL)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.58%
2.71%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):